Cargando…
The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines
OBJECTIVE: Cholangiocarcinoma (CCA) is a noxious malignancy of epithelium of the bile duct with a low response rate to chemotherapy. The epidermal growth factor receptor (EGFR) signaling pathway is implicated in the development of cancerous cells, especially CCA. In this study, we report detailed bi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190356/ https://www.ncbi.nlm.nih.gov/pubmed/33639651 http://dx.doi.org/10.31557/APJCP.2021.22.2.381 |
_version_ | 1783705669346525184 |
---|---|
author | Samatiwat, Papavee Tabtimmai, Lueacha Suphakun, Prapasri Jiwacharoenchai, Nattanan Toviwek, Borvorrnvat Kukongviriyapan, Veerapol Gleeson, M. Paul Choowongkomon, Kiattawee |
author_facet | Samatiwat, Papavee Tabtimmai, Lueacha Suphakun, Prapasri Jiwacharoenchai, Nattanan Toviwek, Borvorrnvat Kukongviriyapan, Veerapol Gleeson, M. Paul Choowongkomon, Kiattawee |
author_sort | Samatiwat, Papavee |
collection | PubMed |
description | OBJECTIVE: Cholangiocarcinoma (CCA) is a noxious malignancy of epithelium of the bile duct with a low response rate to chemotherapy. The epidermal growth factor receptor (EGFR) signaling pathway is implicated in the development of cancerous cells, especially CCA. In this study, we report detailed biological profiling of 13f identified from our earlier hit expansion studies. The aim of this work was to expand our understanding of 13f via more detailed investigations of its mechanism of action against KKU-100, KKU-452 and KKU-M156 CCA cells, as well as in comparison to the EGFR inhibitor Gefitinib and non-specific chemotherapeutic agents such as Cisplatin. METHODS: Inhibiting EGFR-Kinase, cytotoxicity, clonogenic assay, wound healing and apoptosis were performed. Levels of total expression of EGFR and EGFR phosphorylation proteins were detected. RESULTS: 13f was confirmed as an inhibitor of EGFR with an IC(50) value against the tyrosine kinase of EGFR of 22 nM and IC(50) values for 48 h incubation period were 1.3 ± 1.9, 1.5 ± 0.4 and 1.7 ± 1.1 µM of KKU-100, KKU-452 and KKU-M156, respectively through dose- and time-dependent induction of early apoptosis of CCA cells. The compound also suppressed the clonogenic ability of KKU-100 and KKU-M156 cells stronger than Gefitinib, while potently inhibiting EGF-stimulated CCA cell migratory activity in KKU-452 cells. It was observed that under normal conditions EGFR was activated in CCA cells. EGF-stimulated basal expression of EGFR in KKU-452 cells was suppressed following 13f treatment, which was significantly greater than that of the marketed EGFR inhibitor Gefitinib. CONCLUSION: In summary, our study showed that 13f has potent anti-cancer activities including antiproliferation, clonogenic ability and migration through the modulation of EGFR signaling pathway in CCA for the first time. The compound represents an interesting starting point as a potential chemotherapeutic agent in ongoing efforts to improve response rate in CCA patients. |
format | Online Article Text |
id | pubmed-8190356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-81903562021-06-11 The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines Samatiwat, Papavee Tabtimmai, Lueacha Suphakun, Prapasri Jiwacharoenchai, Nattanan Toviwek, Borvorrnvat Kukongviriyapan, Veerapol Gleeson, M. Paul Choowongkomon, Kiattawee Asian Pac J Cancer Prev Research Article OBJECTIVE: Cholangiocarcinoma (CCA) is a noxious malignancy of epithelium of the bile duct with a low response rate to chemotherapy. The epidermal growth factor receptor (EGFR) signaling pathway is implicated in the development of cancerous cells, especially CCA. In this study, we report detailed biological profiling of 13f identified from our earlier hit expansion studies. The aim of this work was to expand our understanding of 13f via more detailed investigations of its mechanism of action against KKU-100, KKU-452 and KKU-M156 CCA cells, as well as in comparison to the EGFR inhibitor Gefitinib and non-specific chemotherapeutic agents such as Cisplatin. METHODS: Inhibiting EGFR-Kinase, cytotoxicity, clonogenic assay, wound healing and apoptosis were performed. Levels of total expression of EGFR and EGFR phosphorylation proteins were detected. RESULTS: 13f was confirmed as an inhibitor of EGFR with an IC(50) value against the tyrosine kinase of EGFR of 22 nM and IC(50) values for 48 h incubation period were 1.3 ± 1.9, 1.5 ± 0.4 and 1.7 ± 1.1 µM of KKU-100, KKU-452 and KKU-M156, respectively through dose- and time-dependent induction of early apoptosis of CCA cells. The compound also suppressed the clonogenic ability of KKU-100 and KKU-M156 cells stronger than Gefitinib, while potently inhibiting EGF-stimulated CCA cell migratory activity in KKU-452 cells. It was observed that under normal conditions EGFR was activated in CCA cells. EGF-stimulated basal expression of EGFR in KKU-452 cells was suppressed following 13f treatment, which was significantly greater than that of the marketed EGFR inhibitor Gefitinib. CONCLUSION: In summary, our study showed that 13f has potent anti-cancer activities including antiproliferation, clonogenic ability and migration through the modulation of EGFR signaling pathway in CCA for the first time. The compound represents an interesting starting point as a potential chemotherapeutic agent in ongoing efforts to improve response rate in CCA patients. West Asia Organization for Cancer Prevention 2021-02 /pmc/articles/PMC8190356/ /pubmed/33639651 http://dx.doi.org/10.31557/APJCP.2021.22.2.381 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Samatiwat, Papavee Tabtimmai, Lueacha Suphakun, Prapasri Jiwacharoenchai, Nattanan Toviwek, Borvorrnvat Kukongviriyapan, Veerapol Gleeson, M. Paul Choowongkomon, Kiattawee The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title | The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title_full | The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title_fullStr | The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title_full_unstemmed | The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title_short | The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines |
title_sort | effect of the egfr - targeting compound 3-[(4-phenylpyrimidin-2-yl) amino] benzene-1-sulfonamide (13f) against cholangiocarcinoma cell lines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190356/ https://www.ncbi.nlm.nih.gov/pubmed/33639651 http://dx.doi.org/10.31557/APJCP.2021.22.2.381 |
work_keys_str_mv | AT samatiwatpapavee theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT tabtimmailueacha theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT suphakunprapasri theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT jiwacharoenchainattanan theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT toviwekborvorrnvat theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT kukongviriyapanveerapol theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT gleesonmpaul theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT choowongkomonkiattawee theeffectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT samatiwatpapavee effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT tabtimmailueacha effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT suphakunprapasri effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT jiwacharoenchainattanan effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT toviwekborvorrnvat effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT kukongviriyapanveerapol effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT gleesonmpaul effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines AT choowongkomonkiattawee effectoftheegfrtargetingcompound34phenylpyrimidin2ylaminobenzene1sulfonamide13fagainstcholangiocarcinomacelllines |